SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Omega Healthcare Investors Inc. – ‘10-K’ for 12/31/21 – ‘EX-101.CAL’

On:  Thursday, 2/17/22, at 11:30am ET   ·   For:  12/31/21   ·   Accession #:  888491-22-7   ·   File #:  1-11316

Previous ‘10-K’:  ‘10-K’ on 2/22/21 for 12/31/20   ·   Next:  ‘10-K’ on 2/14/23 for 12/31/22   ·   Latest:  ‘10-K’ on 2/12/24 for 12/31/23   ·   47 References:   

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 2/17/22  Omega Healthcare Investors Inc.   10-K       12/31/21  155:28M

Annual Report   —   Form 10-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   3.43M 
 8: EX-10.10    Material Contract                                   HTML     47K 
 2: EX-10.6M    Material Contract                                   HTML    100K 
 3: EX-10.6N    Material Contract                                   HTML    116K 
 4: EX-10.6O    Material Contract                                   HTML    108K 
 5: EX-10.6P    Material Contract                                   HTML    125K 
 6: EX-10.6Q    Material Contract                                   HTML    108K 
 7: EX-10.6R    Material Contract                                   HTML    124K 
 9: EX-21.1     Subsidiaries List                                   HTML    199K 
10: EX-22.1     Published Report re: Matters Submitted to a Vote    HTML     41K 
                of Security Holders                                              
11: EX-23.1     Consent of Expert or Counsel                        HTML     41K 
12: EX-31.1     Certification -- §302 - SOA'02                      HTML     45K 
13: EX-31.2     Certification -- §302 - SOA'02                      HTML     45K 
14: EX-32.1     Certification -- §906 - SOA'02                      HTML     42K 
15: EX-32.2     Certification -- §906 - SOA'02                      HTML     41K 
21: R1          Document and Entity Information                     HTML    107K 
22: R2          Consolidated Balance Sheets                         HTML    162K 
23: R3          Consolidated Balance Sheets (Parentheticals)        HTML     57K 
24: R4          Consolidated Statements of Operations               HTML    141K 
25: R5          Consolidated Statements of Comprehensive Income     HTML     72K 
                (Loss)                                                           
26: R6          Consolidated Statements of Changes in Equity        HTML    117K 
27: R7          Consolidated Statements of Changes in Equity        HTML     42K 
                (Parentheticals)                                                 
28: R8          Consolidated Statements of Cash Flows               HTML    158K 
29: R9          Organization                                        HTML     45K 
30: R10         Summary of Significant Accounting Policies          HTML    131K 
31: R11         Real Estate Acquisitions                            HTML    179K 
32: R12         Assets Held for Sale, Dispositions and Impairments  HTML     55K 
33: R13         Contractual Receivables and Other Receivables and   HTML     79K 
                Lease Inducements                                                
34: R14         Leases                                              HTML    106K 
35: R15         Mortgage Notes Receivable                           HTML     84K 
36: R16         Other Investments                                   HTML     83K 
37: R17         Allowance for Credit Losses                         HTML    332K 
38: R18         Variable Interest Entities                          HTML    114K 
39: R19         Investment in Joint Ventures                        HTML    125K 
40: R20         Goodwill and Other Intangibles                      HTML     73K 
41: R21         Concentration of Risk                               HTML     44K 
42: R22         Borrowing Arrangements                              HTML    193K 
43: R23         Derivatives and Hedging                             HTML     60K 
44: R24         Financial Instruments                               HTML    134K 
45: R25         Taxes                                               HTML     82K 
46: R26         Stockholders Equity                                 HTML    154K 
47: R27         Stock-Based Compensation                            HTML    147K 
48: R28         Commitments and Contingencies                       HTML     67K 
49: R29         Supplemental Disclosure to Consolidated Statements  HTML    116K 
                of Cash Flows                                                    
50: R30         Earnings Per Share                                  HTML     87K 
51: R31         Subsequent Events                                   HTML     47K 
52: R32         Schedule Ii - Valuation and Qualifying Accounts     HTML     75K 
53: R33         Schedule Iii - Real Estate and Accumulated          HTML    461K 
                Depreciation                                                     
54: R34         Schedule Iv - Mortgage Loans on Real Estate         HTML    292K 
55: R35         Summary of Significant Accounting Policies          HTML    197K 
                (Policies)                                                       
56: R36         Summary of Significant Accounting Policies          HTML     55K 
                (Tables)                                                         
57: R37         Real Estate Acquisitions (Tables)                   HTML    180K 
58: R38         Assets Held for Sale, Dispositions and Impairments  HTML     49K 
                (Tables)                                                         
59: R39         Contractual Receivables and Other Receivables and   HTML     60K 
                Lease Inducements (Tables)                                       
60: R40         Leases (Tables)                                     HTML    108K 
61: R41         Mortgage Notes Receivable (Tables)                  HTML     65K 
62: R42         Other Investments (Tables)                          HTML     68K 
63: R43         Allowance for Credit Losses (Tables)                HTML    419K 
64: R44         Variable Interest Entities (Tables)                 HTML    118K 
65: R45         Investment in Joint Ventures (Tables)               HTML    123K 
66: R46         Goodwill and Other Intangibles (Tables)             HTML     74K 
67: R47         Borrowing Arrangements (Tables)                     HTML    179K 
68: R48         Derivatives and Hedging (Tables)                    HTML     53K 
69: R49         Financial Instruments (Tables)                      HTML    126K 
70: R50         Taxes (Tables)                                      HTML     79K 
71: R51         Stockholders Equity (Tables)                        HTML    151K 
72: R52         Stock-Based Compensation (Tables)                   HTML    139K 
73: R53         Commitments and Contingencies (Tables)              HTML     51K 
74: R54         Supplemental Disclosure to Consolidated Statements  HTML    115K 
                of Cash Flows (Tables)                                           
75: R55         Earnings Per Share (Tables)                         HTML     86K 
76: R56         Organization and Basis of Presentation (Details)    HTML     45K 
77: R57         Summary of Significant Accounting Policies          HTML    229K 
                (Narrative) (Detail)                                             
78: R58         Summary of Significant Accounting Policies          HTML     54K 
                (Schedule of credit losses impact) (Detail)                      
79: R59         Real Estate Acquisitions (Narrative) (Details)      HTML     87K 
80: R60         Real Estate Acquisitions (Schedule of Significant   HTML    147K 
                Acquisitions) (Detail)                                           
81: R61         Real Estate Acquisitions (Encore Portfolio)         HTML     52K 
                (Narrative) (Detail)                                             
82: R62         Real Estate Acquisitions (MedEquities Merger)       HTML     86K 
                (Narrative) (Detail)                                             
83: R63         Real Estate Acquisitions (Pro Forma Acquisition     HTML     57K 
                Results) (Detail)                                                
84: R64         Real Estate Acquisitions (Fair Value of Assets      HTML     87K 
                Acquired and Liabilities Assumed) (Detail)                       
85: R65         Assets Held for Sale, Dispositions and Impairments  HTML     99K 
                (Narrative) (Details)                                            
86: R66         Assets Held for Sale, Dispositions and Impairments  HTML     43K 
                (Schedule of Properties Held-for-Sale) (Details)                 
87: R67         Contractual Receivables and Other Receivables and   HTML    290K 
                Lease Inducements (Narrative) (Details)                          
88: R68         Contractual Receivables and Other Receivables and   HTML     51K 
                Lease Inducements (Schedule of Net Accounts                      
                Receivable) (Detail)                                             
89: R69         Leases (Narrative) (Detail)                         HTML    109K 
90: R70         Leases (Schedule of operating lease income)         HTML     47K 
                (Details)                                                        
91: R71         Leases (Schedule of estimated contractual rents     HTML     54K 
                due under operating leases) (Details)                            
92: R72         Leases - Balance sheet information (Details)        HTML     48K 
93: R73         Leases (Schedule of Components of Investment in     HTML     58K 
                Direct Financing Leases) (Detail)                                
94: R74         Mortgage Notes Receivable (Narrative) (Detail)      HTML     58K 
95: R75         Mortgage Notes Receivable (Schedule of              HTML     93K 
                Receivables) (Detail)                                            
96: R76         Mortgage Notes Receivable (Notes Due 2027           HTML    115K 
                Narrative) (Detail)                                              
97: R77         Mortgage Notes Receivable (Notes Due 2029           HTML    172K 
                Narrative) (Detail)                                              
98: R78         Mortgage Notes Receivable (Other Mortgage Notes     HTML     88K 
                Outstanding) (Narrative) (Details)                               
99: R79         Other Investments (Schedule of Receivables)         HTML    103K 
                (Details)                                                        
100: R80         Other Investments (Notes Due 2024 Narrative)        HTML     71K  
                (Detail)                                                         
101: R81         Other Investments (Other investments notes due      HTML     77K  
                2024-2025) (Narrative) (Details)                                 
102: R82         Other Investments (Notes Due 2023 Narrative)        HTML     57K  
                (Detail)                                                         
103: R83         Other Investments (Notes Due 2030 Narrative)        HTML     61K  
                (Detail)                                                         
104: R84         Other Investments (Other Investment Note            HTML    126K  
                Narrative) (Detail)                                              
105: R85         Allowance for Credit Losses (Narrative) (Detail)    HTML     63K  
106: R86         Allowance for Credit Losses (Schedule of expected   HTML    185K  
                credit loss per segment) (Detail)                                
107: R87         Allowance for Credit Losses (Schedule by segment    HTML     96K  
                balance by vintage and credit quality indicator)                 
                (Detail)                                                         
108: R88         Variable Interest Entities (Schedule of Variable    HTML    138K  
                Interest Entities) (Detail)                                      
109: R89         Investment in Joint Ventures (Narrative) (Details)  HTML     47K  
110: R90         Investment in Joint Ventures (Schedule of equity    HTML    171K  
                method investments) (Details)                                    
111: R91         Goodwill and Other Intangibles (Narrative)          HTML     56K  
                (Details)                                                        
112: R92         Goodwill and Other Intangibles (Schedule of         HTML     45K  
                Reconciliation of Goodwill) (Detail)                             
113: R93         Goodwill and Other Intangibles (Schedule of         HTML     53K  
                Intangibles) (Detail)                                            
114: R94         Concentration of Risk (Narrative) (Detail)          HTML    101K  
115: R95         Borrowing Arrangements (Schedule of Borrowings)     HTML    223K  
                (Details)                                                        
116: R96         Borrowing Arrangements (HUD Mortgage) (Details)     HTML     81K  
117: R97         Borrowing Arrangements (Revolving Credit Facility)  HTML     62K  
                (Details)                                                        
118: R98         Borrowing Arrangements (OP Term Loan) (Details)     HTML     64K  
119: R99         Borrowing Arrangements (Omega Credit Facilities,    HTML    131K  
                OP Term Loan, Amended 2015 Term Loan Facilities                  
                and General) (Detail)                                            
120: R100        Borrowing Arrangements (Subordinated Debt)          HTML     59K  
                (Narrative) (Detail)                                             
121: R101        Borrowing Arrangements (Schedule of principal       HTML     58K  
                payments, excluding the premium or discount and                  
                the aggregate due thereafter) (Detail)                           
122: R102        Derivatives and Hedging (Narrative) (Details)       HTML    128K  
123: R103        Derivatives and Hedging (Location and the fair      HTML     50K  
                value of derivative instruments designated as                    
                hedges) (Details)                                                
124: R104        Financial Instruments (Schedule of Financial        HTML    124K  
                Instruments) (Details)                                           
125: R105        Taxes (Narrative) (Detail)                          HTML     51K  
126: R106        Taxes (Schedule of components of income tax         HTML     46K  
                expense) (Details)                                               
127: R107        Taxes (Schedule of deferred tax assets and          HTML     49K  
                liabilities) (Detail)                                            
128: R108        Stockholders Equity (Forward Equity Offering)       HTML     54K  
                (Narrative) (Detail)                                             
129: R109        Stockholders Equity (Common Stock Repurchase)       HTML     44K  
                (Narrative) (Detail)                                             
130: R110        Stockholders Equity (At The Market Program          HTML     60K  
                Schedule and Narrative) (Detail)                                 
131: R111        Stockholders Equity (Schedule of dividend           HTML     43K  
                reinvestment and common stock purchase plan)                     
                (Detail)                                                         
132: R112        Stockholders Equity (Schedule of Common Stock       HTML     46K  
                Dividends) (Details)                                             
133: R113        Stockholders Equity (Per Share Distributions)       HTML     48K  
                (Detail)                                                         
134: R114        Stockholders Equity (Schedule of Accumulated Other  HTML    105K  
                Comprehensive Income (Loss)) (Details)                           
135: R115        Stock-Based Compensation (Narrative) (Detail)       HTML     81K  
136: R116        Stock-Based Compensation (Schedule of assumptions   HTML     54K  
                used for estimating fair value of stock awards                   
                using Monte-Carlo model) (Detail)                                
137: R117        Stock-Based Compensation (Schedule of activity in   HTML     81K  
                restricted stock and RSUs) (Detail)                              
138: R118        Commitments and Contingencies (Narrative)           HTML     59K  
                (Details)                                                        
139: R119        Commitments and Contingencies (Schedule of          HTML     47K  
                remaining commitments) (Detail)                                  
140: R120        Supplemental Disclosure to Consolidated Statements  HTML     93K  
                of Cash Flows (Detail)                                           
141: R121        Earnings Per Share (Schedule of Computation of      HTML     91K  
                Basic and Diluted Earnings per Share) (Detail)                   
142: R122        Earnings Per Share (Narrative) (Detail)             HTML     54K  
143: R123        Subsequent Event (Narrative) (Details)              HTML    109K  
144: R124        Schedule Ii - Valuation and Qualifying Accounts     HTML     54K  
                (Detail)                                                         
145: R125        Schedule Iii - Real Estate and Accumulated          HTML    417K  
                Depreciation (Detail)                                            
146: R126        Schedule Iii - Real Estate and Accumulated          HTML     62K  
                Depreciation (Narrative) (Detail)                                
147: R127        Schedule Iii - Real Estate and Accumulated          HTML     51K  
                Depreciation (Narrative 1) (Detail)                              
148: R128        Schedule Iv - Mortgage Loans on Real Estate         HTML    197K  
                (Detail)                                                         
149: R129        Schedule Iv - Mortgage Loans on Real Estate         HTML     56K  
                (Narrative 1) (Detail)                                           
150: R130        Schedule Iv - Mortgage Loans on Real Estate         HTML     44K  
                (Narrative 2) (Detail)                                           
153: XML         IDEA XML File -- Filing Summary                      XML    297K  
151: XML         XBRL Instance -- ohi-20211231x10k_htm                XML   8.35M  
152: EXCEL       IDEA Workbook of Financial Reports                  XLSX    262K  
17: EX-101.CAL  XBRL Calculations -- ohi-20211231_cal                XML    310K 
18: EX-101.DEF  XBRL Definitions -- ohi-20211231_def                 XML   2.14M 
19: EX-101.LAB  XBRL Labels -- ohi-20211231_lab                      XML   2.42M 
20: EX-101.PRE  XBRL Presentations -- ohi-20211231_pre               XML   2.82M 
16: EX-101.SCH  XBRL Schema -- ohi-20211231                          XSD    468K 
154: JSON        XBRL Instance as JSON Data -- MetaLinks              761±  1.18M  
155: ZIP         XBRL Zipped Folder -- 0000888491-22-000007-xbrl      Zip    856K

‘EX-101.CAL’   —   XBRL Calculations — ohi-20211231_cal

This Exhibit is an XBRL XML File.

                                                                                                                                                                                
<?xml version="1.0" encoding="windows-1252"?>
<!-- XBRL document created with Toppan Merrill Bridge 9.6.8042.36810 -->
<!-- Based on XBRL 2.1 -->
<!-- Created on: 2/17/2022 4:22:35 PM -->
<!-- Modified on: 2/17/2022 4:22:35 PM -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
<roleRef xlink:type="simple" xlink:href="ohi-20211231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.omegahealthcare.com/role/StatementConsolidatedBalanceSheets"/>
<roleRef xlink:type="simple" xlink:href="ohi-20211231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.omegahealthcare.com/role/StatementConsolidatedStatementsOfOperations"/>
<roleRef xlink:type="simple" xlink:href="ohi-20211231.xsd#StatementConsolidatedStatementsOfComprehensiveIncomeLoss" roleURI="http://www.omegahealthcare.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss"/>
<roleRef xlink:type="simple" xlink:href="ohi-20211231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.omegahealthcare.com/role/StatementConsolidatedStatementsOfCashFlows"/>
<roleRef xlink:type="simple" xlink:href="ohi-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCreditLossesImpactDetail" roleURI="http://www.omegahealthcare.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCreditLossesImpactDetail"/>
<roleRef xlink:type="simple" xlink:href="ohi-20211231.xsd#DisclosureRealEstateAcquisitionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetail" roleURI="http://www.omegahealthcare.com/role/DisclosureRealEstateAcquisitionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetail"/>
<roleRef xlink:type="simple" xlink:href="ohi-20211231.xsd#DisclosureContractualReceivablesAndOtherReceivablesAndLeaseInducementsScheduleOfNetAccountsReceivableDetail" roleURI="http://www.omegahealthcare.com/role/DisclosureContractualReceivablesAndOtherReceivablesAndLeaseInducementsScheduleOfNetAccountsReceivableDetail"/>
<roleRef xlink:type="simple" xlink:href="ohi-20211231.xsd#DisclosureLeasesScheduleOfOperatingLeaseIncomeDetails" roleURI="http://www.omegahealthcare.com/role/DisclosureLeasesScheduleOfOperatingLeaseIncomeDetails"/>
<roleRef xlink:type="simple" xlink:href="ohi-20211231.xsd#DisclosureLeasesScheduleOfEstimatedContractualRentsDueUnderOperatingLeasesDetails" roleURI="http://www.omegahealthcare.com/role/DisclosureLeasesScheduleOfEstimatedContractualRentsDueUnderOperatingLeasesDetails"/>
<roleRef xlink:type="simple" xlink:href="ohi-20211231.xsd#DisclosureLeasesScheduleOfComponentsOfInvestmentsInDirectFinancingLeasesDetails" roleURI="http://www.omegahealthcare.com/role/DisclosureLeasesScheduleOfComponentsOfInvestmentsInDirectFinancingLeasesDetails"/>
<roleRef xlink:type="simple" xlink:href="ohi-20211231.xsd#DisclosureMortgageNotesReceivableScheduleOfReceivablesDetail" roleURI="http://www.omegahealthcare.com/role/DisclosureMortgageNotesReceivableScheduleOfReceivablesDetail"/>
<roleRef xlink:type="simple" xlink:href="ohi-20211231.xsd#DisclosureOtherInvestmentsScheduleOfReceivablesDetails" roleURI="http://www.omegahealthcare.com/role/DisclosureOtherInvestmentsScheduleOfReceivablesDetails"/>
<roleRef xlink:type="simple" xlink:href="ohi-20211231.xsd#DisclosureAllowanceForCreditLossesScheduleBySegmentBalanceByVintageAndCreditQualityIndicatorDetail" roleURI="http://www.omegahealthcare.com/role/DisclosureAllowanceForCreditLossesScheduleBySegmentBalanceByVintageAndCreditQualityIndicatorDetail"/>
<roleRef xlink:type="simple" xlink:href="ohi-20211231.xsd#DisclosureVariableInterestEntitiesScheduleOfVariableInterestEntitiesDetails" roleURI="http://www.omegahealthcare.com/role/DisclosureVariableInterestEntitiesScheduleOfVariableInterestEntitiesDetails"/>
<roleRef xlink:type="simple" xlink:href="ohi-20211231.xsd#DisclosureGoodwillAndOtherIntangiblesScheduleOfIntangiblesDetail" roleURI="http://www.omegahealthcare.com/role/DisclosureGoodwillAndOtherIntangiblesScheduleOfIntangiblesDetail"/>
<roleRef xlink:type="simple" xlink:href="ohi-20211231.xsd#DisclosureBorrowingArrangementsScheduleOfBorrowingsDetails" roleURI="http://www.omegahealthcare.com/role/DisclosureBorrowingArrangementsScheduleOfBorrowingsDetails"/>
<roleRef xlink:type="simple" xlink:href="ohi-20211231.xsd#DisclosureBorrowingArrangementsScheduleOfPrincipalPaymentsExcludingPremiumOrDiscountAndAggregateDueThereafterDetail" roleURI="http://www.omegahealthcare.com/role/DisclosureBorrowingArrangementsScheduleOfPrincipalPaymentsExcludingPremiumOrDiscountAndAggregateDueThereafterDetail"/>
<roleRef xlink:type="simple" xlink:href="ohi-20211231.xsd#DisclosureFinancialInstrumentsScheduleOfFinancialInstrumentsDetails" roleURI="http://www.omegahealthcare.com/role/DisclosureFinancialInstrumentsScheduleOfFinancialInstrumentsDetails"/>
<roleRef xlink:type="simple" xlink:href="ohi-20211231.xsd#DisclosureTaxesScheduleOfComponentsOfIncomeTaxExpenseDetails" roleURI="http://www.omegahealthcare.com/role/DisclosureTaxesScheduleOfComponentsOfIncomeTaxExpenseDetails"/>
<roleRef xlink:type="simple" xlink:href="ohi-20211231.xsd#DisclosureTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail" roleURI="http://www.omegahealthcare.com/role/DisclosureTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"/>
<roleRef xlink:type="simple" xlink:href="ohi-20211231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfRemainingCommitmentsDetail" roleURI="http://www.omegahealthcare.com/role/DisclosureCommitmentsAndContingenciesScheduleOfRemainingCommitmentsDetail"/>
<roleRef xlink:type="simple" xlink:href="ohi-20211231.xsd#DisclosureSupplementalDisclosureToConsolidatedStatementsOfCashFlowsDetail" roleURI="http://www.omegahealthcare.com/role/DisclosureSupplementalDisclosureToConsolidatedStatementsOfCashFlowsDetail"/>
<roleRef xlink:type="simple" xlink:href="ohi-20211231.xsd#DisclosureEarningsPerShareScheduleOfComputationOfBasicAndDilutedEarningsPerShareDetail" roleURI="http://www.omegahealthcare.com/role/DisclosureEarningsPerShareScheduleOfComputationOfBasicAndDilutedEarningsPerShareDetail"/>
<roleRef xlink:type="simple" xlink:href="ohi-20211231.xsd#ScheduleScheduleIiiRealEstateAndAccumulatedDepreciationDetail" roleURI="http://www.omegahealthcare.com/role/ScheduleScheduleIiiRealEstateAndAccumulatedDepreciationDetail"/>
<calculationLink xlink:role="http://www.omegahealthcare.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Investments" xlink:label="us-gaap_Investments_637807117321784751"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Investments_637807117321784751" order="1" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="ohi-20211231.xsd#ohi_TotalRealEstateInvestmentsAndMortgageNotesReceivableNet" xlink:label="ohi_TotalRealEstateInvestmentsAndMortgageNotesReceivableNet_637807117321784751"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Investments_637807117321784751" xlink:to="ohi_TotalRealEstateInvestmentsAndMortgageNotesReceivableNet_637807117321784751" order="1" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RealEstateInvestmentPropertyNet" xlink:label="us-gaap_RealEstateInvestmentPropertyNet_637807117321784751"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ohi_TotalRealEstateInvestmentsAndMortgageNotesReceivableNet_637807117321784751" xlink:to="us-gaap_RealEstateInvestmentPropertyNet_637807117321784751" order="1" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RealEstateInvestmentPropertyAtCost" xlink:label="us-gaap_RealEstateInvestmentPropertyAtCost_637807117321784751"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_RealEstateInvestmentPropertyNet_637807117321784751" xlink:to="us-gaap_RealEstateInvestmentPropertyAtCost_637807117321784751" order="1" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentBuildingAndBuildingImprovements" xlink:label="us-gaap_InvestmentBuildingAndBuildingImprovements_637807117321784751"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_RealEstateInvestmentPropertyAtCost_637807117321784751" xlink:to="us-gaap_InvestmentBuildingAndBuildingImprovements_637807117321784751" order="1" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Land" xlink:label="us-gaap_Land_637807117321784751"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_RealEstateInvestmentPropertyAtCost_637807117321784751" xlink:to="us-gaap_Land_637807117321784751" order="2" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopmentInProcess" xlink:label="us-gaap_DevelopmentInProcess_637807117321794654"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_RealEstateInvestmentPropertyAtCost_637807117321784751" xlink:to="us-gaap_DevelopmentInProcess_637807117321794654" order="3" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FixturesAndEquipmentGross" xlink:label="us-gaap_FixturesAndEquipmentGross_637807117321794654"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_RealEstateInvestmentPropertyAtCost_637807117321784751" xlink:to="us-gaap_FixturesAndEquipmentGross_637807117321794654" order="4" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RealEstateInvestmentPropertyAccumulatedDepreciation" xlink:label="us-gaap_RealEstateInvestmentPropertyAccumulatedDepreciation_637807117321794654"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_RealEstateInvestmentPropertyNet_637807117321784751" xlink:to="us-gaap_RealEstateInvestmentPropertyAccumulatedDepreciation_637807117321794654" order="2" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet" xlink:label="us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet_637807117321794654"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ohi_TotalRealEstateInvestmentsAndMortgageNotesReceivableNet_637807117321784751" xlink:to="us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet_637807117321794654" order="2" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DirectFinancingLeaseNetInvestmentInLeaseAfterAllowanceForCreditLoss" xlink:label="us-gaap_DirectFinancingLeaseNetInvestmentInLeaseAfterAllowanceForCreditLoss_637807117321794654"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ohi_TotalRealEstateInvestmentsAndMortgageNotesReceivableNet_637807117321784751" xlink:to="us-gaap_DirectFinancingLeaseNetInvestmentInLeaseAfterAllowanceForCreditLoss_637807117321794654" order="3" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestments" xlink:label="us-gaap_OtherInvestments_637807117321794654"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Investments_637807117321784751" xlink:to="us-gaap_OtherInvestments_637807117321794654" order="2" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="us-gaap_EquityMethodInvestments_637807117321794654"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Investments_637807117321784751" xlink:to="us-gaap_EquityMethodInvestments_637807117321794654" order="3" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RealEstateHeldforsale" xlink:label="us-gaap_RealEstateHeldforsale_637807117321804669"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Investments_637807117321784751" xlink:to="us-gaap_RealEstateHeldforsale_637807117321804669" order="4" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637807117321804669"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637807117321804669" order="2" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_637807117321804669"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_637807117321804669" order="3" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet_637807117321804669"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_ContractWithCustomerAssetNet_637807117321804669" order="4" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables_637807117321804669"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherReceivables_637807117321804669" order="5" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill_637807117321804669"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill_637807117321804669" order="6" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets_637807117321814750"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssets_637807117321814750" order="7" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_636788413903472430"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637807117321814750"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_636788413903472430" xlink:to="us-gaap_Liabilities_637807117321814750" order="1" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit_637807117321814750"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637807117321814750" xlink:to="us-gaap_LineOfCredit_637807117321814750" order="1" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebt" xlink:label="us-gaap_SecuredDebt_637807117321814750"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637807117321814750" xlink:to="us-gaap_SecuredDebt_637807117321814750" order="2" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="ohi-20211231.xsd#ohi_SeniorNotesAndOtherUnsecuredBorrowingsNet" xlink:label="ohi_SeniorNotesAndOtherUnsecuredBorrowingsNet_637807117321814750"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637807117321814750" xlink:to="ohi_SeniorNotesAndOtherUnsecuredBorrowingsNet_637807117321814750" order="3" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_637807117321825717"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637807117321814750" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_637807117321825717" order="4" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_637807117321825717"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637807117321814750" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_637807117321825717" order="5" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_637807117321825717"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_636788413903472430" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_637807117321825717" order="2" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637807117321825717"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_637807117321825717" xlink:to="us-gaap_StockholdersEquity_637807117321825717" order="1" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_637807117321825717"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637807117321825717" xlink:to="us-gaap_PreferredStockValue_637807117321825717" order="1" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637807117321834887"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637807117321825717" xlink:to="us-gaap_CommonStockValue_637807117321834887" order="2" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_637807117321834887"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637807117321825717" xlink:to="us-gaap_AdditionalPaidInCapital_637807117321834887" order="3" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637807117321834887"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637807117321825717" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637807117321834887" order="4" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CumulativeDividends" xlink:label="us-gaap_CumulativeDividends_637807117321834887"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637807117321825717" xlink:to="us-gaap_CumulativeDividends_637807117321834887" order="5" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637807117321834887"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637807117321825717" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637807117321834887" order="6" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest_637807117321844663"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_637807117321825717" xlink:to="us-gaap_MinorityInterest_637807117321844663" order="2" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:role="http://www.omegahealthcare.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637807117321844663"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_ProfitLoss_637807117321844663" order="1" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_637807117321844663"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss_637807117321844663" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_637807117321844663" order="1" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_637807117321844663"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_637807117321844663" xlink:to="us-gaap_Revenues_637807117321844663" order="1" use="optional" weight="1" priority="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLeaseIncome" xlink:label="us-gaap_OperatingLeaseLeaseIncome_637807117321844663"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues_637807117321844663" xlink:to="us-gaap_OperatingLeaseLeaseIncome_637807117321844663" order="1" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DirectFinancingLeaseRevenue" xlink:label="us-gaap_DirectFinancingLeaseRevenue_637807117321854845"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues_637807117321844663" xlink:to="us-gaap_DirectFinancingLeaseRevenue_637807117321854845" order="2" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestAndFeeIncomeLoansCommercial" xlink:label="us-gaap_InterestAndFeeIncomeLoansCommercial_637807117321854845"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues_637807117321844663" xlink:to="us-gaap_InterestAndFeeIncomeLoansCommercial_637807117321854845" order="3" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestAndFeeIncomeOtherLoans" xlink:label="us-gaap_InterestAndFeeIncomeOtherLoans_637807117321854845"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues_637807117321844663" xlink:to="us-gaap_InterestAndFeeIncomeOtherLoans_637807117321854845" order="4" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncome" xlink:label="us-gaap_OtherOperatingIncome_637807117321854845"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues_637807117321844663" xlink:to="us-gaap_OtherOperatingIncome_637807117321854845" order="5" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_637807117321854845"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_637807117321844663" xlink:to="us-gaap_OperatingExpenses_637807117321854845" order="2" use="optional" weight="-1" priority="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_637807117321854845"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637807117321854845" xlink:to="us-gaap_DepreciationDepletionAndAmortization_637807117321854845" order="1" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637807117321864664"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637807117321854845" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637807117321864664" order="2" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RealEstateTaxExpense" xlink:label="us-gaap_RealEstateTaxExpense_637807117321864664"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637807117321854845" xlink:to="us-gaap_RealEstateTaxExpense_637807117321864664" order="3" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts_637807117321864664"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637807117321854845" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts_637807117321864664" order="4" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="ohi-20211231.xsd#ohi_ImpairmentRecoveryOfRealEstateNet" xlink:label="ohi_ImpairmentRecoveryOfRealEstateNet_637807117321864664"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637807117321854845" xlink:to="ohi_ImpairmentRecoveryOfRealEstateNet_637807117321864664" order="5" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DirectFinancingLeaseImpairmentLoss" xlink:label="us-gaap_DirectFinancingLeaseImpairmentLoss_637807117321864664"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637807117321854845" xlink:to="us-gaap_DirectFinancingLeaseImpairmentLoss_637807117321864664" order="6" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_637807117321864664"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637807117321854845" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_637807117321864664" order="7" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_637807117321864664"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637807117321854845" xlink:to="us-gaap_InterestExpenseDebt_637807117321864664" order="8" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_637807117321874671"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_637807117321844663" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_637807117321874671" order="3" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="ohi-20211231.xsd#ohi_InvestmentIncomeExpense" xlink:label="ohi_InvestmentIncomeExpense_637807117321874671"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_637807117321874671" xlink:to="ohi_InvestmentIncomeExpense_637807117321874671" order="1" use="optional" weight="1" priority="3"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_637807117321874671"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_637807117321874671" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_637807117321874671" order="2" use="optional" weight="1" priority="3"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_637807117321874671"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_637807117321874671" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_637807117321874671" order="3" use="optional" weight="1" priority="5"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637807117321874671"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss_637807117321844663" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637807117321874671" order="2" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_637807117321874671"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss_637807117321844663" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_637807117321874671" order="3" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_637807117321884657"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_637807117321884657" order="2" use="optional" weight="-1" priority="2"/>
</calculationLink>
<calculationLink xlink:role="http://www.omegahealthcare.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="extended" xlink:title="00300 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_637807117321884657"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_637807117321884657" order="1" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637807117321884657"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_637807117321884657" xlink:to="us-gaap_ProfitLoss_637807117321884657" order="1" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_637807117321884657"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_637807117321884657" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_637807117321884657" order="2" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_637807117321884657"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_637807117321884657" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_637807117321884657" order="1" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_637807117321884657"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_637807117321884657" xlink:to="us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_637807117321884657" order="2" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_637807117321894650"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_637807117321894650" order="2" use="optional" weight="-1"/>
</calculationLink>
<calculationLink xlink:role="http://www.omegahealthcare.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00500 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_636788413903943745"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637807117321894650"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_636788413903943745" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637807117321894650" order="1" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637807117321894650"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637807117321894650" xlink:to="us-gaap_ProfitLoss_637807117321894650" order="1" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_637807117321894650"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637807117321894650" xlink:to="us-gaap_DepreciationDepletionAndAmortization_637807117321894650" order="2" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfRealEstate" xlink:label="us-gaap_ImpairmentOfRealEstate_637807117321894650"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637807117321894650" xlink:to="us-gaap_ImpairmentOfRealEstate_637807117321894650" order="3" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DirectFinancingLeaseImpairmentLoss" xlink:label="us-gaap_DirectFinancingLeaseImpairmentLoss_637807117321894650"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637807117321894650" xlink:to="us-gaap_DirectFinancingLeaseImpairmentLoss_637807117321894650" order="4" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="ohi-20211231.xsd#ohi_ProvisionForRentalIncome" xlink:label="ohi_ProvisionForRentalIncome_637807117321894650"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637807117321894650" xlink:to="ohi_ProvisionForRentalIncome_637807117321894650" order="5" use="optional" weight="1" priority="4"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_637807117321904696"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637807117321894650" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_637807117321904696" order="6" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="ohi-20211231.xsd#ohi_AmortizationOfDeferredFinancingAndRefinancingCosts" xlink:label="ohi_AmortizationOfDeferredFinancingAndRefinancingCosts_637807117321904696"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637807117321894650" xlink:to="ohi_AmortizationOfDeferredFinancingAndRefinancingCosts_637807117321904696" order="7" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="ohi-20211231.xsd#ohi_AccretionOfDirectFinancingLease" xlink:label="ohi_AccretionOfDirectFinancingLease_637807117321904696"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637807117321894650" xlink:to="ohi_AccretionOfDirectFinancingLease_637807117321904696" order="8" use="optional" weight="-1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637807117321904696"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637807117321894650" xlink:to="us-gaap_ShareBasedCompensation_637807117321904696" order="9" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_637807117321904696"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637807117321894650" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_637807117321904696" order="10" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfAboveAndBelowMarketLeases" xlink:label="us-gaap_AmortizationOfAboveAndBelowMarketLeases_637807117321904696"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637807117321894650" xlink:to="us-gaap_AmortizationOfAboveAndBelowMarketLeases_637807117321904696" order="11" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="ohi-20211231.xsd#ohi_IncreaseDecreaseInEffectiveYieldReceivableOnMortgageNotes" xlink:label="ohi_IncreaseDecreaseInEffectiveYieldReceivableOnMortgageNotes_637807117321904696"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637807117321894650" xlink:to="ohi_IncreaseDecreaseInEffectiveYieldReceivableOnMortgageNotes_637807117321904696" order="12" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="ohi-20211231.xsd#ohi_InterestPaidInKind" xlink:label="ohi_InterestPaidInKind_637807117321914662"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637807117321894650" xlink:to="ohi_InterestPaidInKind_637807117321914662" order="13" use="optional" weight="-1" priority="3"/>
<loc xlink:type="locator" xlink:href="ohi-20211231.xsd#ohi_GainLossInEquityMethodInvestmentOperatingActivities" xlink:label="ohi_GainLossInEquityMethodInvestmentOperatingActivities_637807117321914662"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637807117321894650" xlink:to="ohi_GainLossInEquityMethodInvestmentOperatingActivities_637807117321914662" order="14" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerAsset_637807117321914662"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637807117321894650" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerAsset_637807117321914662" order="15" use="optional" weight="-1" priority="3"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StraightLineRent" xlink:label="us-gaap_StraightLineRent_637807117321914662"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637807117321894650" xlink:to="us-gaap_StraightLineRent_637807117321914662" order="16" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="ohi-20211231.xsd#ohi_IncreaseDecreaseInLeaseInducement" xlink:label="ohi_IncreaseDecreaseInLeaseInducement_637807117321914662"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637807117321894650" xlink:to="ohi_IncreaseDecreaseInLeaseInducement_637807117321914662" order="17" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_637807117321914662"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637807117321894650" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_637807117321914662" order="18" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637807117321914662"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_636788413903943745" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637807117321914662" order="2" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_637807117321924825"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637807117321914662" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_637807117321924825" order="1" use="optional" weight="-1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireCommercialRealEstate" xlink:label="us-gaap_PaymentsToAcquireCommercialRealEstate_637807117321924825"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637807117321914662" xlink:to="us-gaap_PaymentsToAcquireCommercialRealEstate_637807117321924825" order="2" use="optional" weight="-1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForDepositsOnRealEstateAcquisitions" xlink:label="us-gaap_PaymentsForDepositsOnRealEstateAcquisitions_637807117321924825"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637807117321914662" xlink:to="us-gaap_PaymentsForDepositsOnRealEstateAcquisitions_637807117321924825" order="3" use="optional" weight="-1" priority="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForConstructionInProcess" xlink:label="us-gaap_PaymentsForConstructionInProcess_637807117321924825"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637807117321914662" xlink:to="us-gaap_PaymentsForConstructionInProcess_637807117321924825" order="4" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfLoansAndLeasesHeldForInvestment" xlink:label="us-gaap_ProceedsFromSaleOfLoansAndLeasesHeldForInvestment_637807117321924825"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637807117321914662" xlink:to="us-gaap_ProceedsFromSaleOfLoansAndLeasesHeldForInvestment_637807117321924825" order="5" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMortgageNotesReceivable" xlink:label="us-gaap_PaymentsToAcquireMortgageNotesReceivable_637807117321935197"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637807117321914662" xlink:to="us-gaap_PaymentsToAcquireMortgageNotesReceivable_637807117321935197" order="6" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:label="us-gaap_PaymentsToAcquireInterestInJointVenture_637807117321935197"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637807117321914662" xlink:to="us-gaap_PaymentsToAcquireInterestInJointVenture_637807117321935197" order="7" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfInterestInJointVenture" xlink:label="us-gaap_ProceedsFromDivestitureOfInterestInJointVenture_637807117321935197"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637807117321914662" xlink:to="us-gaap_ProceedsFromDivestitureOfInterestInJointVenture_637807117321935197" order="8" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfRealEstateHeldforinvestment" xlink:label="us-gaap_ProceedsFromSaleOfRealEstateHeldforinvestment_637807117321935197"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637807117321914662" xlink:to="us-gaap_ProceedsFromSaleOfRealEstateHeldforinvestment_637807117321935197" order="9" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForCapitalImprovements" xlink:label="us-gaap_PaymentsForCapitalImprovements_637807117321935197"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637807117321914662" xlink:to="us-gaap_PaymentsForCapitalImprovements_637807117321935197" order="10" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromInsuranceSettlementInvestingActivities" xlink:label="us-gaap_ProceedsFromInsuranceSettlementInvestingActivities_637807117321935197"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637807117321914662" xlink:to="us-gaap_ProceedsFromInsuranceSettlementInvestingActivities_637807117321935197" order="11" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndCollectionOfOtherReceivables" xlink:label="us-gaap_ProceedsFromSaleAndCollectionOfOtherReceivables_637807117321944683"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637807117321914662" xlink:to="us-gaap_ProceedsFromSaleAndCollectionOfOtherReceivables_637807117321944683" order="12" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments" xlink:label="us-gaap_PaymentsToAcquireOtherInvestments_637807117321944683"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637807117321914662" xlink:to="us-gaap_PaymentsToAcquireOtherInvestments_637807117321944683" order="13" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndCollectionOfMortgageNotesReceivable" xlink:label="us-gaap_ProceedsFromSaleAndCollectionOfMortgageNotesReceivable_637807117321944683"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637807117321914662" xlink:to="us-gaap_ProceedsFromSaleAndCollectionOfMortgageNotesReceivable_637807117321944683" order="14" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637807117321944683"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_636788413903943745" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637807117321944683" order="3" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders" xlink:label="us-gaap_ProceedsFromMinorityShareholders_637807117321954749"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637807117321944683" xlink:to="us-gaap_ProceedsFromMinorityShareholders_637807117321954749" order="1" use="optional" weight="1" priority="3"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_637807117321954749"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637807117321944683" xlink:to="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_637807117321954749" order="2" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfOtherLongTermDebt" xlink:label="us-gaap_RepaymentsOfOtherLongTermDebt_637807117321954749"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637807117321944683" xlink:to="us-gaap_RepaymentsOfOtherLongTermDebt_637807117321954749" order="3" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_637807117321954749"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637807117321944683" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_637807117321954749" order="4" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="ohi-20211231.xsd#ohi_NetProceedsFromIssuanceOfCommonStock" xlink:label="ohi_NetProceedsFromIssuanceOfCommonStock_637807117321954749"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637807117321944683" xlink:to="ohi_NetProceedsFromIssuanceOfCommonStock_637807117321954749" order="5" use="optional" weight="1" priority="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividends" xlink:label="us-gaap_PaymentsOfDividends_637807117321964656"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637807117321944683" xlink:to="us-gaap_PaymentsOfDividends_637807117321964656" order="6" use="optional" weight="-1" priority="1"/>
<loc xlink:type="locator" xlink:href="ohi-20211231.xsd#ohi_RedemptionOfOpUnits" xlink:label="ohi_RedemptionOfOpUnits_637807117321964656"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637807117321944683" xlink:to="ohi_RedemptionOfOpUnits_637807117321964656" order="7" use="optional" weight="-1" priority="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="us-gaap_PaymentsToMinorityShareholders_637807117321964656"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637807117321944683" xlink:to="us-gaap_PaymentsToMinorityShareholders_637807117321964656" order="8" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637807117321964656"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_636788413903943745" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637807117321964656" order="4" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:role="http://www.omegahealthcare.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCreditLossesImpactDetail" xlink:type="extended" xlink:title="40202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of credit losses impact) (Detail)">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivableCollectivelyEvaluatedForImpairment" xlink:label="us-gaap_FinancingReceivableCollectivelyEvaluatedForImpairment"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset" xlink:label="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset_637807117321974665"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinancingReceivableCollectivelyEvaluatedForImpairment" xlink:to="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset_637807117321974665" order="1" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet" xlink:label="us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet_637807117321974665"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinancingReceivableCollectivelyEvaluatedForImpairment" xlink:to="us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet_637807117321974665" order="2" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestments" xlink:label="us-gaap_OtherInvestments_637807117321974665"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinancingReceivableCollectivelyEvaluatedForImpairment" xlink:to="us-gaap_OtherInvestments_637807117321974665" order="3" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DirectFinancingLeaseNetInvestmentInLeaseAfterAllowanceForCreditLoss" xlink:label="us-gaap_DirectFinancingLeaseNetInvestmentInLeaseAfterAllowanceForCreditLoss_637807117321974665"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinancingReceivableCollectivelyEvaluatedForImpairment" xlink:to="us-gaap_DirectFinancingLeaseNetInvestmentInLeaseAfterAllowanceForCreditLoss_637807117321974665" order="4" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:role="http://www.omegahealthcare.com/role/DisclosureRealEstateAcquisitionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetail" xlink:type="extended" xlink:title="40306 - Disclosure - REAL ESTATE ACQUISITIONS (Fair Value of Assets Acquired and Liabilities Assumed) (Detail)">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_637807117321984655"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_637807117321984655" order="1" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_637807117321984655"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_637807117321984655" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_637807117321984655" order="1" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_637807117321984655"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_637807117321984655" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_637807117321984655" order="2" use="optional" weight="1" priority="3"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_637807117321984655"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_637807117321984655" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_637807117321984655" order="3" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="ohi-20211231.xsd#ohi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestmentInUnconsolidatedJointVenture" xlink:label="ohi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestmentInUnconsolidatedJointVenture_637807117321984655"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_637807117321984655" xlink:to="ohi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestmentInUnconsolidatedJointVenture_637807117321984655" order="4" use="optional" weight="1" priority="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_637807117321984655"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_637807117321984655" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_637807117321984655" order="5" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="ohi-20211231.xsd#ohi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherInvestments" xlink:label="ohi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherInvestments_637807117321984655"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_637807117321984655" xlink:to="ohi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherInvestments_637807117321984655" order="6" use="optional" weight="1" priority="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialAssets_637807117321984655"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_637807117321984655" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialAssets_637807117321984655" order="7" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_637807117321994897"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_637807117321984655" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_637807117321994897" order="8" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_637807117321994897"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_637807117321994897" order="2" use="optional" weight="-1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_637807117321994897"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_637807117321994897" order="3" use="optional" weight="-1" priority="2"/>
</calculationLink>
<calculationLink xlink:role="http://www.omegahealthcare.com/role/DisclosureContractualReceivablesAndOtherReceivablesAndLeaseInducementsScheduleOfNetAccountsReceivableDetail" xlink:type="extended" xlink:title="40502 - Disclosure - CONTRACTUAL RECEIVABLES AND OTHER RECEIVABLES AND LEASE INDUCEMENTS (Schedule of Net Accounts Receivable) (Detail)">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable_637807117321994897"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_InterestReceivable_637807117321994897" order="1" use="optional" weight="1" priority="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentReceivablesNet" xlink:label="us-gaap_DeferredRentReceivablesNet_637807117321994897"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_DeferredRentReceivablesNet_637807117321994897" order="2" use="optional" weight="1" priority="1"/>
<loc xlink:type="locator" xlink:href="ohi-20211231.xsd#ohi_InducementsToLease" xlink:label="ohi_InducementsToLease_637807117321994897"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherReceivables" xlink:to="ohi_InducementsToLease_637807117321994897" order="3" use="optional" weight="1" priority="2"/>
</calculationLink>
<calculationLink xlink:role="http://www.omegahealthcare.com/role/DisclosureLeasesScheduleOfOperatingLeaseIncomeDetails" xlink:type="extended" xlink:title="40602 - Disclosure - LEASES (Schedule of operating lease income) (Details)">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLeaseIncome" xlink:label="us-gaap_OperatingLeaseLeaseIncome"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:label="us-gaap_OperatingLeaseLeaseIncomeLeasePayments_637807117322004690"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLeaseIncome" xlink:to="us-gaap_OperatingLeaseLeaseIncomeLeasePayments_637807117322004690" order="1" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseVariableLeaseIncome" xlink:label="us-gaap_OperatingLeaseVariableLeaseIncome_637807117322004690"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLeaseIncome" xlink:to="us-gaap_OperatingLeaseVariableLeaseIncome_637807117322004690" order="2" use="optional" weight="1" priority="2"/>
</calculationLink>
<calculationLink xlink:role="http://www.omegahealthcare.com/role/DisclosureLeasesScheduleOfEstimatedContractualRentsDueUnderOperatingLeasesDetails" xlink:type="extended" xlink:title="40603 - Disclosure - LEASES (Schedule of estimated contractual rents due under operating leases) (Details)">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_637807117322004690"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_637807117322004690" order="1" use="optional" weight="1" priority="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_637807117322004690"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_637807117322004690" order="2" use="optional" weight="1" priority="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_637807117322004690"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_637807117322004690" order="3" use="optional" weight="1" priority="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_637807117322004690"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_637807117322004690" order="4" use="optional" weight="1" priority="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_637807117322014670"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_637807117322014670" order="5" use="optional" weight="1" priority="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter_637807117322014670"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter_637807117322014670" order="6" use="optional" weight="1" priority="1"/>
</calculationLink>
<calculationLink xlink:role="http://www.omegahealthcare.com/role/DisclosureLeasesScheduleOfComponentsOfInvestmentsInDirectFinancingLeasesDetails" xlink:type="extended" xlink:title="40605 - Disclosure - LEASES - Schedule of components of investments in direct financing leases (Details)">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DirectFinancingLeaseNetInvestmentInLeaseAfterAllowanceForCreditLoss" xlink:label="us-gaap_DirectFinancingLeaseNetInvestmentInLeaseAfterAllowanceForCreditLoss_2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DirectFinancingLeaseNetInvestmentInLeaseAllowanceForCreditLoss" xlink:label="us-gaap_DirectFinancingLeaseNetInvestmentInLeaseAllowanceForCreditLoss_637807117322014670"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DirectFinancingLeaseNetInvestmentInLeaseAfterAllowanceForCreditLoss_2" xlink:to="us-gaap_DirectFinancingLeaseNetInvestmentInLeaseAllowanceForCreditLoss_637807117322014670" order="1" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DirectFinancingLeaseNetInvestmentInLease" xlink:label="us-gaap_DirectFinancingLeaseNetInvestmentInLease_637807117322014670"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DirectFinancingLeaseNetInvestmentInLeaseAfterAllowanceForCreditLoss_2" xlink:to="us-gaap_DirectFinancingLeaseNetInvestmentInLease_637807117322014670" order="2" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DirectFinancingLeaseDeferredSellingProfit" xlink:label="us-gaap_DirectFinancingLeaseDeferredSellingProfit_637807117322014670"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DirectFinancingLeaseNetInvestmentInLease_637807117322014670" xlink:to="us-gaap_DirectFinancingLeaseDeferredSellingProfit_637807117322014670" order="1" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DirectFinancingLeaseLeaseReceivable" xlink:label="us-gaap_DirectFinancingLeaseLeaseReceivable_637807117322014670"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DirectFinancingLeaseNetInvestmentInLease_637807117322014670" xlink:to="us-gaap_DirectFinancingLeaseLeaseReceivable_637807117322014670" order="2" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:role="http://www.omegahealthcare.com/role/DisclosureMortgageNotesReceivableScheduleOfReceivablesDetail" xlink:type="extended" xlink:title="40702 - Disclosure - MORTGAGE NOTES RECEIVABLE (Schedule of Receivables) (Detail)">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet" xlink:label="us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableGross" xlink:label="us-gaap_NotesReceivableGross_637807117322024778"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet" xlink:to="us-gaap_NotesReceivableGross_637807117322024778" order="1" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLosses_637807117322024778"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet" xlink:to="us-gaap_FinancingReceivableAllowanceForCreditLosses_637807117322024778" order="2" use="optional" weight="-1"/>
</calculationLink>
<calculationLink xlink:role="http://www.omegahealthcare.com/role/DisclosureOtherInvestmentsScheduleOfReceivablesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - OTHER INVESTMENTS (Schedule of Receivables) (Details)">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestments" xlink:label="loc_us-gaap_OtherInvestments"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableGross" xlink:label="us-gaap_NotesReceivableGross_637807117322024778"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherInvestments" xlink:to="us-gaap_NotesReceivableGross_637807117322024778" order="1" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLosses_637807117322024778"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherInvestments" xlink:to="us-gaap_FinancingReceivableAllowanceForCreditLosses_637807117322024778" order="2" use="optional" weight="-1"/>
</calculationLink>
<calculationLink xlink:role="http://www.omegahealthcare.com/role/DisclosureAllowanceForCreditLossesScheduleBySegmentBalanceByVintageAndCreditQualityIndicatorDetail" xlink:type="extended" xlink:title="40903 - Disclosure - ALLOWANCE FOR CREDIT LOSSES (Schedule by segment balance by vintage and credit quality indicator) (Detail)">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableGross" xlink:label="us-gaap_NotesReceivableGross"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivableOriginatedInCurrentFiscalYear" xlink:label="us-gaap_FinancingReceivableOriginatedInCurrentFiscalYear_637807117322034802"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NotesReceivableGross" xlink:to="us-gaap_FinancingReceivableOriginatedInCurrentFiscalYear_637807117322034802" order="1" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivableOriginatedInFiscalYearBeforeLatestFiscalYear" xlink:label="us-gaap_FinancingReceivableOriginatedInFiscalYearBeforeLatestFiscalYear_637807117322034802"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NotesReceivableGross" xlink:to="us-gaap_FinancingReceivableOriginatedInFiscalYearBeforeLatestFiscalYear_637807117322034802" order="2" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivableOriginatedTwoYearsBeforeLatestFiscalYear" xlink:label="us-gaap_FinancingReceivableOriginatedTwoYearsBeforeLatestFiscalYear_637807117322034802"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NotesReceivableGross" xlink:to="us-gaap_FinancingReceivableOriginatedTwoYearsBeforeLatestFiscalYear_637807117322034802" order="3" use="optional" weight="1" priority="3"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivableOriginatedThreeYearsBeforeLatestFiscalYear" xlink:label="us-gaap_FinancingReceivableOriginatedThreeYearsBeforeLatestFiscalYear_637807117322034802"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NotesReceivableGross" xlink:to="us-gaap_FinancingReceivableOriginatedThreeYearsBeforeLatestFiscalYear_637807117322034802" order="4" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivableOriginatedFourYearsBeforeLatestFiscalYear" xlink:label="us-gaap_FinancingReceivableOriginatedFourYearsBeforeLatestFiscalYear_637807117322034802"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NotesReceivableGross" xlink:to="us-gaap_FinancingReceivableOriginatedFourYearsBeforeLatestFiscalYear_637807117322034802" order="5" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="ohi-20211231.xsd#ohi_FinancingReceivableOriginatedFiveYearsBeforeLatestFiscalYear" xlink:label="ohi_FinancingReceivableOriginatedFiveYearsBeforeLatestFiscalYear_637807117322034802"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NotesReceivableGross" xlink:to="ohi_FinancingReceivableOriginatedFiveYearsBeforeLatestFiscalYear_637807117322034802" order="6" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="ohi-20211231.xsd#ohi_FinancingReceivableOriginatedSixOrMoreYearsBeforeLatestFiscalYear" xlink:label="ohi_FinancingReceivableOriginatedSixOrMoreYearsBeforeLatestFiscalYear_637807117322034802"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NotesReceivableGross" xlink:to="ohi_FinancingReceivableOriginatedSixOrMoreYearsBeforeLatestFiscalYear_637807117322034802" order="7" use="optional" weight="1" priority="3"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivableRevolving" xlink:label="us-gaap_FinancingReceivableRevolving_637807117322044679"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NotesReceivableGross" xlink:to="us-gaap_FinancingReceivableRevolving_637807117322044679" order="8" use="optional" weight="1" priority="2"/>
</calculationLink>
<calculationLink xlink:role="http://www.omegahealthcare.com/role/DisclosureVariableInterestEntitiesScheduleOfVariableInterestEntitiesDetails" xlink:type="extended" xlink:title="41001 - Disclosure - VARIABLE INTEREST ENTITIES (Schedule of variable interest entities) (Details)">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_1"/>
<loc xlink:type="locator" xlink:href="ohi-20211231.xsd#ohi_InducementsToLease" xlink:label="ohi_InducementsToLease_637807117322044679"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets_1" xlink:to="ohi_InducementsToLease_637807117322044679" order="1" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="ohi-20211231.xsd#ohi_DeferredRentReceivablesPayableNetNoncurrent" xlink:label="ohi_DeferredRentReceivablesPayableNetNoncurrent_637807117322044679"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets_1" xlink:to="ohi_DeferredRentReceivablesPayableNetNoncurrent_637807117322044679" order="2" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet_637807117322044679"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets_1" xlink:to="us-gaap_ContractWithCustomerAssetNet_637807117322044679" order="3" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestments" xlink:label="us-gaap_OtherInvestments_637807117322044679"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets_1" xlink:to="us-gaap_OtherInvestments_637807117322044679" order="4" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RealEstateInvestmentPropertyNet" xlink:label="us-gaap_RealEstateInvestmentPropertyNet_637807117322044679"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets_1" xlink:to="us-gaap_RealEstateInvestmentPropertyNet_637807117322044679" order="5" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RealEstateHeldforsale" xlink:label="us-gaap_RealEstateHeldforsale_637807117322054915"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets_1" xlink:to="us-gaap_RealEstateHeldforsale_637807117322054915" order="6" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
<loc xlink:type="locator" xlink:href="ohi-20211231.xsd#ohi_ContingentLiability" xlink:label="ohi_ContingentLiability_637807117322054915"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="ohi_ContingentLiability_637807117322054915" order="1" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDepositLiability" xlink:label="us-gaap_SecurityDepositLiability_637807117322054915"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_SecurityDepositLiability_637807117322054915" order="2" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="ohi-20211231.xsd#ohi_NetInPlaceLeaseLiability" xlink:label="ohi_NetInPlaceLeaseLiability_637807117322054915"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="ohi_NetInPlaceLeaseLiability_637807117322054915" order="3" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:role="http://www.omegahealthcare.com/role/DisclosureGoodwillAndOtherIntangiblesScheduleOfIntangiblesDetail" xlink:type="extended" xlink:title="41203 - Disclosure - GOODWILL AND OTHER INTANGIBLES (Schedule of Intangibles) (Detail)">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BelowMarketLeaseNet" xlink:label="us-gaap_BelowMarketLeaseNet_636788413905969098"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BelowMarketLeaseGross" xlink:label="us-gaap_BelowMarketLeaseGross_637807117322054915"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BelowMarketLeaseNet_636788413905969098" xlink:to="us-gaap_BelowMarketLeaseGross_637807117322054915" order="1" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BelowMarketLeaseAccumulatedAmortization" xlink:label="us-gaap_BelowMarketLeaseAccumulatedAmortization_637807117322064927"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BelowMarketLeaseNet_636788413905969098" xlink:to="us-gaap_BelowMarketLeaseAccumulatedAmortization_637807117322064927" order="2" use="optional" weight="-1"/>
</calculationLink>
<calculationLink xlink:role="http://www.omegahealthcare.com/role/DisclosureBorrowingArrangementsScheduleOfBorrowingsDetails" xlink:type="extended" xlink:title="41401 - Disclosure - BORROWING ARRANGEMENTS (Schedule of Borrowings) (Details)">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebt" xlink:label="us-gaap_UnsecuredDebt_637807117322064927"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_UnsecuredDebt_637807117322064927" order="1" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebt" xlink:label="us-gaap_SecuredDebt_637807117322064927"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_SecuredDebt_637807117322064927" order="2" use="optional" weight="1" priority="2"/>
</calculationLink>
<calculationLink xlink:role="http://www.omegahealthcare.com/role/DisclosureBorrowingArrangementsScheduleOfPrincipalPaymentsExcludingPremiumOrDiscountAndAggregateDueThereafterDetail" xlink:type="extended" xlink:title="41407 - Disclosure - BORROWING ARRANGEMENTS (Schedule of principal payments, excluding the premium or discount and the aggregate due thereafter) (Detail)">
<loc xlink:type="locator" xlink:href="ohi-20211231.xsd#ohi_LongTermDebtMaturingInYearsOneThroughFiveAndThereafter" xlink:label="ohi_LongTermDebtMaturingInYearsOneThroughFiveAndThereafter_636788413906310061"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_637807117322064927"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ohi_LongTermDebtMaturingInYearsOneThroughFiveAndThereafter_636788413906310061" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_637807117322064927" order="1" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_637807117322064927"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ohi_LongTermDebtMaturingInYearsOneThroughFiveAndThereafter_636788413906310061" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_637807117322064927" order="2" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_637807117322074661"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ohi_LongTermDebtMaturingInYearsOneThroughFiveAndThereafter_636788413906310061" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_637807117322074661" order="3" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_637807117322074661"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ohi_LongTermDebtMaturingInYearsOneThroughFiveAndThereafter_636788413906310061" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_637807117322074661" order="4" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_637807117322074661"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ohi_LongTermDebtMaturingInYearsOneThroughFiveAndThereafter_636788413906310061" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_637807117322074661" order="5" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_637807117322074661"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ohi_LongTermDebtMaturingInYearsOneThroughFiveAndThereafter_636788413906310061" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_637807117322074661" order="6" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:role="http://www.omegahealthcare.com/role/DisclosureFinancialInstrumentsScheduleOfFinancialInstrumentsDetails" xlink:type="extended" xlink:title="41601 - Disclosure - FINANCIAL INSTRUMENTS (Schedule of Financial Instruments) (Details)">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
<loc xlink:type="locator" xlink:href="ohi-20211231.xsd#ohi_CapitalLeasesNetInvestmentIndirectFinancingLeasesFairValueDisclosure" xlink:label="ohi_CapitalLeasesNetInvestmentIndirectFinancingLeasesFairValueDisclosure_637807117322074661"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="ohi_CapitalLeasesNetInvestmentIndirectFinancingLeasesFairValueDisclosure_637807117322074661" order="1" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="ohi-20211231.xsd#ohi_MortgageLoansOnRealEstateFairValueDisclosure" xlink:label="ohi_MortgageLoansOnRealEstateFairValueDisclosure_637807117322074661"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="ohi_MortgageLoansOnRealEstateFairValueDisclosure_637807117322074661" order="2" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableFairValueDisclosure" xlink:label="us-gaap_NotesReceivableFairValueDisclosure_637807117322074661"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_NotesReceivableFairValueDisclosure_637807117322074661" order="3" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LinesOfCreditFairValueDisclosure" xlink:label="us-gaap_LinesOfCreditFairValueDisclosure_637807117322084744"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LinesOfCreditFairValueDisclosure_637807117322084744" order="1" use="optional" weight="1" priority="1"/>
<loc xlink:type="locator" xlink:href="ohi-20211231.xsd#ohi_SecuredBorrowingsFairValueDisclosure" xlink:label="ohi_SecuredBorrowingsFairValueDisclosure_637807117322084744"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="ohi_SecuredBorrowingsFairValueDisclosure_637807117322084744" order="2" use="optional" weight="1" priority="1"/>
<loc xlink:type="locator" xlink:href="ohi-20211231.xsd#ohi_SterlingTermLoanFairValue" xlink:label="ohi_SterlingTermLoanFairValue_637807117322084744"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="ohi_SterlingTermLoanFairValue_637807117322084744" order="3" use="optional" weight="1" priority="1"/>
<loc xlink:type="locator" xlink:href="ohi-20211231.xsd#ohi_OmegaOpTermLoanFairValue" xlink:label="ohi_OmegaOpTermLoanFairValue_637807117322084744"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="ohi_OmegaOpTermLoanFairValue_637807117322084744" order="4" use="optional" weight="1" priority="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="us-gaap_NotesPayableFairValueDisclosure_637807117322084744"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_NotesPayableFairValueDisclosure_637807117322084744" order="5" use="optional" weight="1" priority="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:label="us-gaap_LongTermDebtFairValue_637807117322084744"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LongTermDebtFairValue_637807117322084744" order="6" use="optional" weight="1" priority="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisSubordinatedDebtObligations" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisSubordinatedDebtObligations_637807117322084744"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisSubordinatedDebtObligations_637807117322084744" order="7" use="optional" weight="1" priority="1"/>
</calculationLink>
<calculationLink xlink:role="http://www.omegahealthcare.com/role/DisclosureTaxesScheduleOfComponentsOfIncomeTaxExpenseDetails" xlink:type="extended" xlink:title="41702 - Disclosure - TAXES (Schedule of components of income tax expense) (Details)">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
<loc xlink:type="locator" xlink:href="ohi-20211231.xsd#ohi_CurrentAndDeferredFederalStateAndLocalIncomeTaxExpenseBenefit" xlink:label="ohi_CurrentAndDeferredFederalStateAndLocalIncomeTaxExpenseBenefit_637807117322094673"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="ohi_CurrentAndDeferredFederalStateAndLocalIncomeTaxExpenseBenefit_637807117322094673" order="1" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_637807117322094673"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_637807117322094673" order="2" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:role="http://www.omegahealthcare.com/role/DisclosureTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail" xlink:type="extended" xlink:title="41703 - Disclosure - TAXES (Schedule of deferred tax assets and liabilities) (Detail)">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
<loc xlink:type="locator" xlink:href="ohi-20211231.xsd#ohi_DeferredTaxLiabilitiesForeignBasisAndTimingDifferences" xlink:label="ohi_DeferredTaxLiabilitiesForeignBasisAndTimingDifferences_637807117322094673"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="ohi_DeferredTaxLiabilitiesForeignBasisAndTimingDifferences_637807117322094673" order="1" use="optional" weight="1" priority="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637807117322094673"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637807117322094673" order="2" use="optional" weight="-1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_637807117322094673"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_637807117322094673" order="3" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:role="http://www.omegahealthcare.com/role/DisclosureCommitmentsAndContingenciesScheduleOfRemainingCommitmentsDetail" xlink:type="extended" xlink:title="42002 - Disclosure - COMMITMENTS AND CONTINGENCIES (Schedule of remaining commitments) (Detail)">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment_637807117322104765"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:to="us-gaap_OtherCommitment_637807117322104765" order="1" use="optional" weight="1" priority="1"/>
<loc xlink:type="locator" xlink:href="ohi-20211231.xsd#ohi_AmountsFundedUnderCommitment" xlink:label="ohi_AmountsFundedUnderCommitment_637807117322104765"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:to="ohi_AmountsFundedUnderCommitment_637807117322104765" order="2" use="optional" weight="-1" priority="1"/>
</calculationLink>
<calculationLink xlink:role="http://www.omegahealthcare.com/role/DisclosureSupplementalDisclosureToConsolidatedStatementsOfCashFlowsDetail" xlink:type="extended" xlink:title="42101 - Disclosure - SUPPLEMENTAL DISCLOSURE TO CONSOLIDATED STATEMENTS OF CASH FLOWS (Detail)">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637807117322104765"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637807117322104765" order="1" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_637807117322104765"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_637807117322104765" order="2" use="optional" weight="1" priority="2"/>
</calculationLink>
<calculationLink xlink:role="http://www.omegahealthcare.com/role/DisclosureEarningsPerShareScheduleOfComputationOfBasicAndDilutedEarningsPerShareDetail" xlink:type="extended" xlink:title="42201 - Disclosure - EARNINGS PER SHARE (Schedule of Computation of Basic and Diluted Earnings per Share) (Detail)">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637807117322114690"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637807117322114690" order="1" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_637807117322114690"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_637807117322114690" order="2" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToEquityForwardAgreements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToEquityForwardAgreements_637807117322114690"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_IncrementalCommonSharesAttributableToEquityForwardAgreements_637807117322114690" order="3" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="ohi-20211231.xsd#ohi_NoncontrollingInterestOperatingPartnershipUnits" xlink:label="ohi_NoncontrollingInterestOperatingPartnershipUnits_637807117322114690"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="ohi_NoncontrollingInterestOperatingPartnershipUnits_637807117322114690" order="4" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:role="http://www.omegahealthcare.com/role/ScheduleScheduleIiiRealEstateAndAccumulatedDepreciationDetail" xlink:type="extended" xlink:title="42501 - Schedule - SCHEDULE III - REAL ESTATE AND ACCUMULATED DEPRECIATION (Detail)">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RealEstateGrossAtCarryingValue" xlink:label="us-gaap_RealEstateGrossAtCarryingValue_636788413907262543"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RealEstateAndAccumulatedDepreciationCarryingAmountOfLand" xlink:label="us-gaap_RealEstateAndAccumulatedDepreciationCarryingAmountOfLand_637807117322114690"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_RealEstateGrossAtCarryingValue_636788413907262543" xlink:to="us-gaap_RealEstateAndAccumulatedDepreciationCarryingAmountOfLand_637807117322114690" order="1" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RealEstateAndAccumulatedDepreciationCarryingAmountOfBuildingsAndImprovements" xlink:label="us-gaap_RealEstateAndAccumulatedDepreciationCarryingAmountOfBuildingsAndImprovements_637807117322114690"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_RealEstateGrossAtCarryingValue_636788413907262543" xlink:to="us-gaap_RealEstateAndAccumulatedDepreciationCarryingAmountOfBuildingsAndImprovements_637807117322114690" order="2" use="optional" weight="1"/>
</calculationLink>
</link:linkbase>

5 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/12/24  Omega Healthcare Investors Inc.   10-K       12/31/23  156:32M
 2/14/23  Omega Healthcare Investors Inc.   10-K       12/31/22  150:30M
11/03/22  Omega Healthcare Investors Inc.   10-Q        9/30/22  112:16M
 8/02/22  Omega Healthcare Investors Inc.   10-Q        6/30/22  110:16M
 5/03/22  Omega Healthcare Investors Inc.   10-Q        3/31/22  103:13M

42 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 1/27/22  Omega Healthcare Investors Inc.   8-K:5,7,9   1/27/22   12:443K                                   Toppan Merrill/FA
 5/20/21  Omega Healthcare Investors Inc.   8-K:8,9     5/20/21   14:1M                                     Toppan Merrill/FA
 5/04/21  Omega Healthcare Investors Inc.   8-K:1,2,9   4/30/21   12:2.8M                                   Toppan Merrill/FA
 3/10/21  Omega Healthcare Investors Inc.   8-K:1,2,9   3/10/21   14:1M                                     Toppan Merrill/FA
 2/22/21  Omega Healthcare Investors Inc.   10-K       12/31/20  142:28M
11/03/20  Omega Healthcare Investors Inc.   10-Q        9/30/20  113:19M
10/09/20  Omega Healthcare Investors Inc.   8-K:1,2,9  10/07/20   16:1.1M                                   Toppan Merrill/FA
 2/28/20  Omega Healthcare Investors Inc.   10-K       12/31/19  159:33M
12/20/19  Omega Healthcare Investors Inc.   8-K:5,9    12/16/19   13:736K                                   Toppan Merrill/FA
11/08/19  Omega Healthcare Investors Inc.   10-Q        9/30/19  109:16M
 9/20/19  Omega Healthcare Investors Inc.   8-K:1,2,9   9/17/19   16:1.1M                                   Toppan Merrill/FA
 2/26/19  Omega Healthcare Investors Inc.   10-K       12/31/18  157:34M
 1/04/19  Omega Healthcare Investors Inc.   8-K:1,8,9   1/02/19    2:670K                                   Toppan Merrill/FA
 8/08/18  Omega Healthcare Investors Inc.   10-Q        6/30/18   98:11M                                    Toppan Merrill/FA
 6/11/18  Omega Healthcare Investors Inc.   8-K:5,9     6/11/18    2:255K
 2/23/18  Omega Healthcare Investors Inc.   10-K       12/31/17  152:17M                                    Toppan Merrill/FA
 8/09/17  Omega Healthcare Investors Inc.   10-Q        6/30/17  108:9.1M                                   Toppan Vite NY Inc./FA
 5/05/17  Omega Healthcare Investors Inc.   10-Q        3/31/17  100:8.7M                                   Toppan Vite NY Inc./FA
 4/04/17  Omega Healthcare Investors Inc.   8-K:1,2,9   4/04/17   15:2M                                     Toppan Vite NY Inc./FA
 2/24/17  Omega Healthcare Investors Inc.   10-K       12/31/16  141:19M                                    Toppan Vite NY Inc./FA
11/08/16  Omega Healthcare Investors Inc.   10-Q        9/30/16  103:10M                                    Toppan Vite NY Inc./FA
 8/05/16  Omega Healthcare Investors Inc.   10-Q        6/30/16  103:9.7M                                   Toppan Vite NY Inc./FA
 7/12/16  Omega Healthcare Investors Inc.   8-K:1,2,9   7/12/16   15:2.1M                                   Toppan Vite NY Inc./FA
 5/06/16  Omega Healthcare Investors Inc.   10-Q        3/31/16   97:8.4M                                   Toppan Vite NY Inc./FA
 2/29/16  Omega Healthcare Investors Inc.   10-K       12/31/15  134:16M                                    Toppan Vite NY Inc./FA
11/12/15  OHI Asset (IN) Monticello, LLC    S-4                   24:4.4M                                   Toppan Vite NY Inc./FA
11/12/15  Seguin Texas Property, L.L.C.     S-4/A      11/10/15    6:1.9M                                   Toppan Vite NY Inc./FA
11/06/15  Omega Healthcare Investors Inc.   10-Q        9/30/15  101:10M                                    Toppan Vite NY Inc./FA
10/06/15  Yuba Aviv, L.L.C.                 S-4                   38:5.9M                                   Toppan Vite NY Inc./FA
 9/29/15  Omega Healthcare Investors Inc.   8-K:1,2,8,9 9/23/15    3:907K                                   Toppan Vite NY Inc./FA
 9/03/15  Omega Healthcare Investors Inc.   S-3ASR      9/03/15    7:534K                                   Toppan Vite NY Inc./FA
 5/08/15  Omega Healthcare Investors Inc.   10-Q        3/31/15   91:13M                                    Toppan Vite NY Inc./FA
 4/16/15  Tulare County Property, L.L.C.    S-4                   78:7.6M                                   Toppan Vite NY Inc./FA
 4/03/15  Omega Healthcare Investors Inc.   8-K:1,2,5,8 3/31/15   18:8.3M                                   Toppan Vite NY Inc./FA
 3/24/15  Omega Healthcare Investors Inc.   8-K:1,2,9   3/18/15    3:888K                                   Toppan Vite NY Inc./FA
 2/27/15  Omega Healthcare Investors Inc.   10-K       12/31/14  132:27M                                    Toppan Vite NY Inc./FA
 9/11/14  Omega Healthcare Investors Inc.   8-K:1,2,9   9/11/14    3:854K                                   Toppan Vite NY Inc./FA
 8/06/14  Omega Healthcare Investors Inc.   10-Q        6/30/14   81:15M                                    Toppan Vite NY Inc./FA
 3/11/14  Omega Healthcare Investors Inc.   8-K:1,2,9   3/11/14    3:851K                                   Toppan Vite NY Inc./FA
 8/05/13  Omega Healthcare Investors Inc.   10-Q        6/30/13  115:16M                                    Toppan Vite NY Inc./FA
11/07/12  Omega Healthcare Investors Inc.   10-Q        9/30/12   65:13M                                    Toppan Vite NY Inc./FA
 5/02/11  Aviv REIT, Inc.                   S-4         4/29/11  387:17M                                    Donnelley … Solutions/FA
↑Top
Filing Submission 0000888491-22-000007   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Wed., May 15, 6:55:42.5pm ET